AKT1 and Miyoshi myopathy: In MM, inhibiting the PI3K/AKT/mTOR pathway suppresses the proliferation of MM side group (SP) cells, leading to cell cycle arrest, promoting apoptosis (40), inhibiting osteolytic diseases (55), and even enhancing chemotherapy sensitivity to BTZ (56), dexamethasone (57), and melphalan (58, 59), thereby inhibiting the progression of MM.